Literature summary for 2.7.1.137 extracted from

Hudis, C; Swanton, C; Janjigian, YY; Lee, R; Sutherland, S; Lehman, R; Chandarlapaty, S; Hamilton, N; Gajria, D; Knowles, J; Shah, J; Shannon, K; Tetteh, E; Sullivan, DM; Moreno, C; Yan, L; Han, HS
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. (2013), Breast Cancer Res, 15, R110.

Organism

Organism	UniProt	Comment	Textmining

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)